

Horizon2020

SC1 – Health, Demographic change and Wellbeing - Opportunità per il tema Salute (2016-2017)



BRUNO MOURENZA


Horizon 2020

Punto di Contatto Nazionale SC1



UNIVERSITÀ
DEGLI STUDI
DI FERRARA
- EX LABORE FRUCTUS -

H2020/ The Three Pillars



Struttura del programma



Excellent Science

- **European Research Council**
 - Frontier research by the best individual teams
- **Future and Emerging Technologies**
 - Collaborative research to open new fields of innovation
- **Marie Skłodowska Curie actions**
 - Opportunities for training and career development
- **Research infrastructures** (including e-infrastructure)
 - Ensuring access to world-class facilities

Industrial Technologies

- **Leadership in enabling and industrial technologies**
 - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
 - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
 - Fostering all forms of innovation in all types of SMEs

Societal Challenges

- **Health, demographic change and wellbeing**
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

European Institute of Innovation and Technology (EIT)

Spreading Excellence and Widening Participation

Science with and for society

Joint Research Center (JRC)



2° PILLAR

INDUSTRIAL LEADERSHIP






Connections to Health in Pillar II



Industrial Technologies

- **Leadership in enabling and industrial technologies**
 - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
 - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
 - Fostering all forms of innovation in all types of SMEs



Health issues in II PILLAR: NMP-B



Excellent Science

- **European Research Council**
 - Frontier research by the best individual teams
- **Future and Emerging Technologies**
 - Collaborative research to open new fields of innovation
- **Marie Skłodowska-Curie actions**
 - Opportunities for training and career development
- **Research infrastructures** (including e-infrastructure)
 - Ensuring access to world-class facilities

Industrial Technologies

- **Leadership in enabling and industrial technologies**
 - ICT, **Nanotechnologies**, materials, **biotechnology**, manufacturing, space
- **Access to risk finance**
 - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
 - Fostering all forms of innovation in all types of SMEs


Societal Challenges

- **Health, demographic change and wellbeing**
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

Example

BIOTECHNOLOGY
(From topics BIOTEC 01 to 08)

ADVANCED MATERIALS AND NANOTECHNOLOGIES FOR HEALTHCARE
(From topics NMBP 09 to 16)





ADVANCED MATERIALS AND NANOTECHNOLOGIES FOR HEALTHCARE

- NMBP-09-2016: Biomaterials for diagnosis and treatment of **demyelination disorders** of the Central Nervous System
- NMBP-10-2016: Nanoformulation of **biologicals**
- NMBP-12-2017: Development of a reliable methodology for better risk management of **engineered biomaterials** in Advanced Therapy Medicinal Products and/or Medical Devices
- NMBP-13-2017: Cross-cutting KETs for **diagnostics at the point-of-care**
- NMBP-14-2017: Regulatory Science Framework for assessment of risk benefit ratio of **Nanomedicines and Biomaterials**
- NMBP-15-2017: Nanotechnologies for **imaging cellular transplants** and regenerative processes in vivo
- NMBP-16-2017: Mobilising the European **nano-biomedical ecosystem**

BIOTECHNOLOGY

- BIOTEC-03-2016: **Microbial chassis platforms** with optimized metabolic pathways for industrial innovations through systems biology
- BIOTEC-04-2016: KET Biotechnology foresight identifying gaps and high-value opportunities for the EU industry
- BIOTEC-05-2017: **Microbial platforms for CO₂-reuse processes** in the low-carbon economy
- BIOTEC-06-2017: Optimisation of **biocatalysis and downstream processing** for the sustainable production of high value-added platform chemicals



3° PILLAR


SOCIETAL CHALLENGES



HEALTH implications in Societal Challenges

Societal Challenges

- **Health, demographic change and wellbeing**
- **Food security, sustainable agriculture, marine and maritime research & the bioeconomy**
- **Secure, clean and efficient energy**
- **Smart, green and integrated transport**
- **Climate action, resource efficiency and raw materials**
- **Inclusive, innovative and reflective societies**
- **Security society**



Societal Challenge 2- Food...



Excellent Science

- **European Research Council**
 - Frontier research by the best individual teams
- **Future and Emerging Technologies**
 - Collaborative research to open new fields of innovation
- **Marie Skłodowska Curie actions**
 - Opportunities for training and career development
- **Research infrastructures** (including e-infrastructure)
 - Ensuring access to world-class facilities

Industrial Technologies

- **Leadership in enabling and industrial technologies**
 - ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
 - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
 - Fostering all forms of innovation in all types of SMEs

Societal Challenges

- **Health, demographic change and wellbeing**
- **Food security, sustainable agriculture, marine and maritime research & the bioeconomy**
- **Secure, clean and efficient energy**
- **Smart, green and integrated transport**
- **Climate action, resource efficiency and raw materials**
- **Inclusive, innovative and reflective societies**
- **Security society**

Examples

Healthy and safe foods and diets for all

SFS-37-2016: The impact of consumer practices in food safety: risks and mitigation strategies

SFS-38-2016: Impulsivity and compulsivity and the link with nutrition, lifestyle and the socio-economic environment

SFS-39-2017: How to tackle the childhood obesity epidemic.

SFS-40-2017: Sweeteners and sweetness enhancers.

Linking healthy oceans and seas for healthy people


BG-06-2017: Interaction between people, oceans and seas: a strategic approach towards healthcare and well-being

BG-07-2017: Blue green innovation for clean coasts and seas.

BG-08-2017: Innovative sustainable solutions for improving the safety and dietary properties of seafood



Societal Challenge 7- Security



CIP- CIP 1 – 2016 AND 2017: Prevention, detection, response and mitigation of the combination of physical and threats to the critical infrastructure of Europe.
 Scope: proposals should focus on one of the following critical infrastructures: water system, energy infrastructure, transport infrastructure, health services, and financial services

SEC – DRS 1 -2016: Integrated tools for response planning and scenario building

Scope: disaster risks (natural, accidental, or intentional) should be addressed in the context of:

- The EU Civil Protection Mechanism (Decision 1313/2013), which paves the way for reinforced cooperation in civil protection assistance interventions for the protection primarily of people, and also of the environment and property in the event of natural and man-made disasters, emergency situations in case of mass events, acts of terrorism and technological, chemical. Biological, radiological or environmental accidents

SEC- DRS 3 -2016: Validation of biological toxins measurements after an incident: Development of tools and procedures for quality control

Scope: By their characteristics, biological toxins are in between the classical chemical and biological toxins, and are covered both by the Chemical Weapons Conventions (CWC) and Biological Weapons Convention (BWC). The large variability among families of biological toxins complicates their measurement and unambiguous identification in human specimens, and environmental or food samples. Toxins are rapidly metabolized and degraded after incorporation, limiting the time window for successful identification and forensic analysis. Proposal should develop quality control tools, as well as the Standard Operating Procedures necessary for establishing a mechanism to systematically validate laboratory-based measurement techniques, including sample preparation strategies and analyses made in-situ issued by mobile and quickly deployable laboratories, which should be proposed for adoption at EU level.

1. HEALTH, DEMOGRAPHIC CHANGE AND WELLBEING



Work Programme SC1 2016-2017



Pers. Medicine

Broad topics

Less prescriptive topic texts

Two-year work programme

Stronger focus on end users

Clinical trials



The SC1 Work Programme 2016-17 in brief

Call 'Personalised Medicine'

21 topics (34 in 2014-2015): 10 in 2016, 10 in 2017,
1 open in 2016 & 2017

including 'coordination activities'

15 topics (17 in 2014-2015): 12 in 2016, 3 in 2017



**€ 935
million**

SME Instrument : 2 Topics

Other Actions: 12 items

(incl. InnovFin ID & "Birth Day Prize")

Focus Area Digital Security: 1 Topic


Focus Area Internet of Things: 1 Topic

Personalised medicine – towards a definition

*"Personalised medicine refers to a **medical model** using molecular profiling for tailoring the **right therapeutic strategy for the right person at the right time**, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention"*




Health in H2020



- Health solutions can imply different phases of research and innovation

STRUCTURE OF THE PROGRAMME: WHERE HEALTH could fit?



How to read a topic ?



PHC 2 – 2015: Understanding diseases: systems medicine

Specific challenge: The development of new improved understanding of the often very complex (bio) medicine approaches have the potential to transform a variety of biological and medical research data. A collaborative approach is required to assemble the data from biology, medicine, mathematics, computational science and medicine approaches.

Scope: Proposals should focus on new avenues to study phenotypes in multifactorial diseases and/or the development/optimisation and/or application of systems of biomedical and clinical data to produce or refine computational and mathematical approaches. The approaches should be validated in well-phenotyped patient cohorts, taking into account potential thoroughly investigated.

The Commission considers that proposals requesting up to EUR 4 and 6 million would allow this specific challenge. Nonetheless, this does not preclude submission of proposals for smaller amounts.

Expected impact: This will provide:

- Leverage of existing investments in Europe
- New directions for better disease detection and diagnosis
- Systems medicine tools and approaches that will be implemented which represent an improvement over existing approaches

Type of action: Research and Innovation action

- **'PM-08 – 2017'**
- **'Specific challenge'**
sets the context, the problem to be addressed, why intervention is necessary
- **'Scope'**
delineates the problem, specifies the focus and the boundaries of the potential action BUT without describing specific approaches
- **'Expected impact'**
describe the key elements of what is expected to be achieved in relation to the specific challenge
- **'Type of action'**

What's next? WP 2016-2017

1.1 Understanding health, well-being and disease

SC1-PM-01-2016: Multi omics for personalised therapies addressing **diseases of the immune system**

SC1-PM-02-2017: New concepts in **patient stratification****

SC1-PM-03-2017: Diagnostic characterisation of **rare diseases**

SC1-PM-04-2016: Networking and optimising the **use of population and patient cohorts** at EU level.

1.2. Preventing disease

SC1-PM-05-2016: The European Human **Biomonitoring** Initiative

SC1-PM-06-2016: Vaccine development for **malaria and/or neglected infectious diseases**

SC1-PM-07-2017: Promoting **mental health** and well-being in the young**

1.3. Treating and managing disease

SC1-PM-08-2017: New therapies for **rare diseases****

SC1-PM-09-2016: New therapies for **chronic diseases**

SC1-PM-10-2017: Comparing the effectiveness of existing **healthcare interventions in the adult population****

SC1-PM-11-2016-2017: Clinical research on **regenerative medicine**



** *two-stages evaluation*

What's next? WP 2016-2017



1.4. Active ageing and self-management of health

SC1-PM-12–2016: PCP - **eHealth innovation** in empowering the patient

SC1-PM-13–2016: PPI for deployment and scaling up of **ICT solutions for active and healthy ageing**

SC1-PM-14–2016: EU-Japan cooperation on Novel ICT **Robotics** based solutions for active and healthy ageing at home or in care facilities

SC1-PM-15-2017: **Personalized coaching for well-being and care of people as they age**

1.5. Methods and data

SC1-PM-16–2017: In-silico trials for developing and assessing **biomedical products**

SC1-PM-17–2017: Personalised **computer models and in-silico systems** for well-being

SC1-PM-18–2016: **Big Data** supporting Public Health policies

SC1-PM-19–2017: PPI for uptake of standards for the **exchange of digitalised healthcare records**

SC1-PM-20-2017: Development of new methods and **measures for improved economic evaluation and efficiency measures in the health sector**

1.6. Health care provision and integrated care

SC1-PM-21-2016: Implementation research for **scaling-up of evidence based innovations and good practice** in Europe and low- and middle-income countries

SME instrument in SC1 work programme 2016-2017




SMEInst-05-2016-2017 – Supporting innovative SMEs in the healthcare biotechnology sector

a) Cell technologies in medical applications (all phase 1 and phase 2 deadlines in 2016 and 2017)

b) Clinical research for the validation of biomarkers and/or diagnostic medical devices (only at the first cut-off date in 2017 and for phase 2 applications)

SMEInst-06-2016-2017 – Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

Template for essential information to be provided for proposals including clinical trials / studies / investigations



The use of this template is mandatory for all clinical studies included in a proposal submitted to topics **PM-01, PM-02, PM-06, PM-07, PM-08, PM-09, PM-10, PM-11 and HCO-07**. For these topics, you will have the possibility to upload the completed template as a separate part of your application in the submission system.

Some advices:

- Addition of Annex 2: **Mandatory deliverables** for clinical studies.
- Proposals containing clinical studies submitted to **topics not listed** can use template as an orientation and provide information in concept and approach or in work packages.
- **Risk and contingency plans** have to be addressed in part B3.2 and table 3.2a.
- Clinical centers whose contribution is limited to **subject recruitment or treatment** may have status of full beneficiary: always preferred!
- **Third parties/subcontractors** must be identified in the DoA.
- **3 unique and exclusive (!) personnel categories**: Doctors, Other medical personnel, Technical personnel. (categories for 'nurses' 'study nurses' or 'pharmacists' do not exist!).



SC1 and international cooperation

- Reference to specific **multi-lateral initiatives**
- Mutual opening of research programmes with **Third Countries (USA)**
- Funding of Third Countries entities by their **own funding agencies** for participating to Horizon 2020 (Switzerland, Australia)
- Specific actions



Strategic Initiatives around HEALTH



Innovative Medicines Initiative 2

www.imi.europa.eu



European Innovation Partnership on Active and Healthy Ageing

<https://webgate.ec.europa.eu/eipaha>



Active and Assisted Living 2

www.aal-europe.eu



European & Developing Countries Clinical Trials Partnership (EDCTP2)

www.edctp.org

ALTRE OPPORTUNITÀ DI FINANZIAMENTO NEL SETTORE DELLA SALUTE






innovative
medicines
initiative



|||U|||9|||A|||G

IMI 2 budget



EFPIA = **E**uropean **F**ederation of **P**harmaceutical **I**ndustries and **A**ssociation

* Imaging, Diagnostics, IT for health etc.

The IMI portfolio



Innovative Medicines Initiative

■ Corporate contribution


■ IMI funding

Partners

AiCuris	Johnson&Johnson
Animal Health	Medimmune
Division of Sanofi	Merck
Astellas	Merck Sharp & Dohme Corp
AstraZeneca	Merial
Basilea	Novartis
Boehringer Ingelheim	Pfizer
Cubist	Pfizer
GSK	Rempex
Janssen	Sanofi

AstraZeneca	Novartis
Bayer	Pfizer
Janssen	Sanofi
Lundbeck	UCB
Merck	

Abbott	Janssen
AbbVie	Lundbeck
AC IMMUNE	Merck
Amgen	Novartis
Astellas	NOVO NORDISK
AstraZeneca	Orion Corporation
BOGEN IDEC	Pfizer
Boehringer Ingelheim	Roche
Eisai	Sanofi
Eli Lilly	SERVIER
ESTEVE	UCB
Grunenthal	Vifor
GSK	



efpia



Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes/Metabolic disorders
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines




The right prevention and treatment
for the right patient at the right time

Strategic Research Agenda for
Innovative Medicines Initiative 2

**Aligned with
WHO priorities**

A Typical IMI Consortium



Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises (\leq €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

- EU Member States
- Associated Countries

Other countries:

No funding **unless**

- **participation deemed essential** by IMI for carrying out the action
- **Annual Work Plan / Calls documents**


New! At least three legal entities



In IMI2: a more attractive funding model

New!

- For all beneficiaries eligible for funding and all activities:
 - **100% reimbursement** of eligible costs for Research & Innovation projects
 - **Flat rate of 25%** reimbursement for indirect costs



IMI 2 – Call 8 includes the following topic:

- *Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks*

The indicative budget for the entire period of 2 years is **€70 million**.

Deadlines

The Call will remain **open for two years**, with the following **cut-off dates**:

- 16 March 2016
- 15 September 2016
- 16 March 2017
- 14 September 2017
- 15 March 2018


IMI 2 – Call 9 includes the following topic:

The following topics are included on this IMI 2 - Call 9, the **deadline is 27th July 2016**:

- Addressing the **clinical burden of Clostridium difficile infection (CDI)**: evaluation of the burden, current practices and set up of a European research platform
- Development of **immune tolerance therapies for the treatment of rheumatic diseases**
- **Data quality** in preclinical research and development
- Next generation of **electronic translational safety – NEXGETS**
- Identification and validation of non-invasive markers across the spectrum of **nonalcoholic fatty liver disease (NAFLD)**
- Joint **influenza vaccine** effectiveness surveillance

Stay in touch

- Visit our website
www.imi.europa.eu
- Sign up to our newsletter
bit.ly/IMInewsletter
- Follow us on Twitter
[@IMI_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group
bit.ly/LinkedInIMI
- E-mail us
infodesk@imi.europa.eu





Directorate-General for
Health & Consumers

DG SANCO

Third Health Programme 2014-2020



CONSUMERS

Il programma si concentra su **quattro obiettivi principali**, il cui scopo è conseguire un forte potenziale di crescita economica grazie al miglior stato di salute:

- 1) **Sviluppare strumenti e meccanismi comuni a livello dell'UE per affrontare la carenza di risorse umane e finanziarie, al fine di contribuire a sistemi sanitari innovativi e sostenibili;**
- 2) **Migliorare l'accesso alle competenze mediche e alle informazioni concernenti patologie specifiche anche su scala transnazionale e sviluppare soluzioni condivise e orientamenti per migliorare la qualità della sanità e della sicurezza dei pazienti.**
- 3) **Individuare, diffondere e promuovere l'adozione di buone pratiche convalidate per prevenire le malattie e promuovere la buona salute.**
- 4) **Sviluppare approcci comuni per proteggere i cittadini dalle minacce sanitarie transfrontaliere.**

CHI NE BENEFICERÀ E COME

- **Direttamente**: tutte le amministrazioni pubbliche nazionali ed europee attive nell'assistenza sanitaria, e gli organismi privati, le ONG e i gruppi di interesse che promuovono politiche e sistemi sanitari più adatti alle attuali sfide demografiche e sociali.
- **Indirettamente**: tutti gli europei, grazie a una migliore assistenza sanitaria, alla promozione della salute e a misure di prevenzione.

La **partecipazione** è aperta ad una vasta gamma di organizzazioni, tra cui:

- **Gli Istituti di Ricerca , Università e Ospedali**
- **Gli enti pubblici**
- **ONG**
- **Imprese Commerciali**

The EU grant is limited to a **maximum co-funding rate of 60% of eligible costs**. In case of exceptional utility up to 80% can be granted (see Work Plan 2016, Annex VII).

Le dotazioni finanziarie per l'attuazione del programma per il periodo dal 1° gennaio 2014 al 31 dicembre 2020 ammonteranno a **449,4 milioni di EUR**.

Ultimi bandi!!!!

Deadline: 2nd June 2016

TITLE	INDICATIVE AMOUNT, EUR	Ref. in Work Plan 2016	Grants foreseen
Migrants' health: Best practices in care provision for vulnerable migrants and refugees	4.500.000	2.1.1.1	one or more
Gathering knowledge and exchanging best practices on measures reducing underage drinking and heavy episodic drinking	1.200.000	2.1.1.2	one or more
Gathering knowledge and exchanging best practises to on measures to prevent illicit drug use in line with the minimum quality standards in drug demand reduction	600.000	2.1.1.3	one or more
Support to Member States and stakeholders to address the chronic disease challenge	2.500.000	2.1.1.4	one or more
Donor selection and protection	550.000	2.1.4.3	one or more



Come partecipare?

Vi interessa partecipare al programma per la salute?

Tutte le **informazioni, insieme al modulo di candidatura**, sono disponibili qui:
[Agenzia Esecutiva per i Consumatori, Salute, Agricoltura e Alimentazione - CHAFAEA](#)

Il referente nel nostro paese

Contattate il referente nel vostro paese per ottenere assistenza e consigli:

Punto focale nazionale

Dr Giovanni NICOLETTI
Ministero della Salute
nfp_eahc@sanita.it



Per ulteriori informazioni:

<http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/hp/>

Active & Healthy Ageing

*A European Innovation
Partnership*







European Innovation Partnership on Active & Healthy Ageing



crosscutting, connecting & engaging **stakeholders** across sectors, from private & public sector

+2 HLY by 2020
Triple win for Europe



Action Groups

-  Improving prescriptions and adherence to treatment
-  Better management of health: preventing falls
-  Preventing functional decline & frailty
-  Integrated care for chronic conditions, inc. telecare
-  ICT solutions for independent living & active ageing
-  Age-friendly cities and environments

I settori d'intervento prioritari sono stati individuati nel piano strategico di attuazione e nel piano operativo, adottati nel 2011 dal gruppo direttivo incaricato dell'avvio e dell'attuazione della partnership.

Per realizzare il piano tutti i soggetti interessati hanno iniziato a collaborare nell'ambito di gruppi d'azione.

- ✓ Action Group A1: Prescription and adherence action at regional level.
- ✓ Action Group A2: Personalized health management: Falls prevention.
- ✓ Action Group A3: Prevention of functional decline and frailty.
- ✓ Action Group B3: Integrated care for chronic diseases, including remote monitoring at regional level.
- ✓ Action Group C2: Interoperable independent living solutions.
- ✓ Action Group D4: Age friendly buildings, cities and environments.

Stakeholders wishing to get involved in the advancing of Specific Actions have formed **Action Groups** through the "Invitation for Commitment" application process.

In each Action Group, stakeholders commit to running a number of activities, contributing towards the headline target, starting with the creation and implementation of an Action Plan.

E' attivo online anche un "**Marketplace per idee innovative**", che rientra in EIP.

E' uno spazio interattivo per scambiare opinioni, trovare partners o iniziative al fine di mettere in pratica delle idee innovative:

<https://webgate.ec.europa.eu/eipaha/>



Per ulteriori Informazioni:

http://ec.europa.eu/research/innovation-union/index_en.cfm?section=active-healthy-ageing




JPND

research

EU Joint Programme – Neurodegenerative Disease Research

EU Joint Programme – Neurodegenerative Disease Research



La strategia del JPND rappresenta una visione per coordinare la ricerca nell'ambito delle malattie neurodegenerative, in particolare l'**Alzheimer**. Si affronta l'intero spettro di attività di ricerca che è necessario per affrontare il peso crescente di queste patologie per il prossimo decennio e oltre.

L'obiettivo del **Programma Congiunto (JPND)*** è quello di migliorare rapidamente la nostra comprensione delle cause di questo tipo di malattie. Oltre a **fornire ai medici gli strumenti per diagnosticare e trattare queste malattie** sin dalla fase precoce, il JPND dovrebbe anche portare ad un **migliore sistema di assistenza sanitaria e sociale** sia per i pazienti che per chi si prende cura di loro.

*The JPND diseases are:

Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD related disorders, Prion disease, Motor neurone diseases (MND), Huntington's Disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA)

Implementation Plan

A first-phase JPND Implementation Plan has been agreed for the **period of 2012-2014**.
The plan has these major action areas:

Annual Calls for Proposals

Action Groups to determine research needs and opportunities

Action Groups to promote engagement, commitment and partnerships

Annual Calls for Proposals

JPND intends to launch Calls for proposals each year to address high priority areas in neurodegenerative disease research. Over the period of 2012-2014, it is anticipated that JPND will launch calls to address each of the following priority areas:

*In general: **Minimum 3 and maximum of 6** research groups (principal investigators) **from at least 3 different countries** of the funding organizations participating in this call*

<http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/open-calls/>

NEW Partnering Tool

<http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/partnering-tool/>

Per ulteriori informazioni:

Adriana Maggi, Ph.D.

Member of the JPND Management Board

Director Center of Excellence on Neurodegenerative Diseases University of Milan

adriana.maggi@unimi.it



JPND website

<http://www.neurodegenerationresearch.eu/home/>

secretariat@jpnd.eu



SERVIZI A SUPPORTO DEL NETWORKING

E RICERCA DI NUOVI PARTNER

Welcome to HealthCompetence

This website includes all projects related to life science and health supported by the European Commission since 2004. It gives visibility to organisations and scientists involved in these projects and, together with interactive search devices, facilitates the identification of potential collaboration partners and the set up of partnerships between academia and industry in health research.

HealthCompetence will also progressively give access to the research results in terms of technology offers, patents and publications.



Simple Search

Search



Upcoming Events



Project Search

find Projects by research field, country and more.

Go >>



Person Search

find Organisations and Persons

Go >>



Generate your report

use a set of reports to answer your questions on research funded by the European Commission

Go >>

www.HealthCompetence.eu
An open, pan-European infrastructure for information on research projects & results within Health Science

Help & Support:

support@avedas.com

Online Survey:

Please take part in our survey
HealthCompetence Online Survey



Coordinated by AVEDAS in collaboration with EFB and InsermTransfert.
Financed and supported by European Commission - Directorate - General for Research and Innovation

OVERVIEW

Number of Projects :	2
Total number of partners :	27
Number of industrial partners :	
Number of academic partners :	13
Number of partner hospitals :	
Earliest start date :	2012-05-01
Latest end date :	2017-04-30

ISTITUTO ONCOLOGICO VENETO



LIST OF PROJECTS (2 of 2)

	Title	Acronym	Instrument	Number of partners	Project funding	Start date	End date
1	Circulating Tumor Cells Therapeutic Apheresis: a novel biotechnology enabling personalized therapy for all cancer patients	CTCTRAP	Collaborative project	12	6,000,000 €	2012-09-01	2016-08-31
2	New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier	TRANS-INT	Collaborative project	17	8,000,000 €	2012-05-01	2017-04-30

KEY RESEARCHERS FOR "ISTITUTO ONCOLOGICO VENETO"

	Firstname	Last name	Organization unit	Number of projects
1	Vincenzo	Bronte	ISTITUTO ONCOLOGICO VENETO	1
2	Rita	Zamarchi	ISTITUTO ONCOLOGICO VENETO	1

LIST OF KEYWORDS (10 of 21)

	Keyword	Number of projects
1	Treatment	2
2	Disease	2
3	Risk Assessment	1
4	Risk	1
5	Polysaccharides	1
6	Polypeptides	1
7	Pharmaceutical Preparations	1
8	Neoplasm Metastasis	1
9	Nanocapsules	1
10	Micelles	1


LIST OF MAIN PARTNER ORGANISATIONS (10 of 27)

	Organisation name	Country	Type	SME	Number of joint projects	Total projects
1	ACZON SRL	Italy	Private for profit	no	1	1
2	ADVANCELL ADVANCED IN VITRO CELL TECHNOLOGIES S.A	Spain	Private for profit	no	1	2
3	AQUAMARIJN MICRO FILTRATION BV	Netherlands	Private for profit	no	1	1
4	ASPER BIOTECH AS	Estonia	Private for profit	no	1	5
5	COMMISSARIAT A L' ENERGIE ATOMIQUE	France	Research organisations	no	1	149
6	EBERHARD KARLS UNIVERSITAET TUEBINGEN	Germany	Higher or secondary education	no	1	100
7	F. HOFFMANN-LA ROCHE AG	Switzerland	Private for profit	no	1	18
8	FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)	Spain	Research organisations	no	1	22
9	Heinrich-Heine-Universitaet Duesseldorf	Germany	Higher or secondary education	no	1	25
10	Institute of Cancer Research - Royal Cancer Hospital	United Kingdom	Higher or secondary education	no	1	23

NETWORK GRAPH WITH MAIN PARTNER ORGANISATIONS

Size of the circles: Calculation based on the number of projects for each organization, i.e. the larger the circle, the more projects the organization has corresponding to the selection criteria in the current report.

Light grey lines: Indicate an existing relation, i.e. if at least one joint project exists between the two organizations.





What are you looking for?

<http://www.fitforhealth.eu/>

Latest News



New Testimonies of SMEs



Publish Your Profile

Present your companies or research institutes research field and expertise through filling the proposed profiling form! Your profile will be entered into FFH database.



Publish Your Partner Search

Are you a coordinator of a research consortia preparing a project proposal for an open call in Horizon 2020 funded research in the Health sector and look for SME partners?



Find Your Partners

Search the Fit for Health 2.0 database for expertise profiles of SMEs and research institutes interested in becoming involved in Horizon 2020 research projects.



Create a new Profile

Fields with * are required.

I. Organisation Details

Research Activities *

II. FP European Projects

Former participation in an FP European Project?

No Yes

Project Title / Acronym

Activities performed

III. Expertise / Commitments Offered

Keywords specifying the expertise *

Description of the expertise *

Commitment offered *

- technology development
- dissemination
- demonstration
- research
- training

If other commitment offered, please specify here

Call Topics

Select Topics



For complete topics description, please refer to work programme available here (http://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/main/h2020-wp1415-health_en.pdf)

IV. Expectations

Term Commitment *

Short (<1 year) Medium (1 to 3 years) Long (> 3 years)

Expected results for your organisation *

V. Personal Information

Would you agree that your identity is displayed with the profile? Should you prefer confidential treatment of your identity, only the expert in service of your profile will be displayed...

Display my identity with this profile:

No Yes

Create

euMatch v3.0 © 2014 Eurotop. (<http://eurotop.be/>)

Create a new Project

Fields with * are required.

I. Project Details

Project Title *

Acronym

Project Types *

- Research and Innovation Action (RIA) - 100% funding scheme
- SME-Instrument
- Pre-Commercial Procurement (PCP)
- Inducement Prize
- ERA-NET Co-fund (only for member states)
- Innovation Action (IA) - 70% funding scheme
- Fast Track to Innovation (FT2)
- Public Procurement of Innovative Solutions (PPI)
- Coordination and Support Action (CSA)

If other project type, please specify here

Status *

- Planned for submission Running project

Call Topics

Select Topics

For complete topics description, please refer to work programme available here (http://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/main/h2020-wp1415-health_en.pdf)

Main Research Areas *

Project Description *

Keywords *

Partners already involved

Project estimated budget (€)

Estimated budget reserved for SMEs (€)

II. Profile of SME or other Organization Sought

Roles *

- technology development
- dissemination
- demonstration
- research
- training

If other role, please specify here

Country / Region *

Start of Partnership *

- Start-up phase Mid-term End-phase

Expertise required *

III. Personal Information

Would you agree that your identity is displayed with the profile? Should you prefer confidential treatment of your identity, only the expert in service of your profile will be displayed...

Publish User Info

- No Yes

Create





A chi rivolgersi per un supporto?

Participant portal:

<http://ec.europa.eu/research/participants/portal/desktop/en/home.html>

Per progetti finanziati:

http://cordis.europa.eu/projects/home_en.html



➔ Punti di Contatto Nazionali (APRE)

➔ Informazioni pratiche & consigli sulle procedure e regole di partecipazione

➔ National delegates in Programme Committees

➔ Interpretazione scientifica dei bandi, input all'elaborazione dei Work Programme

➔ European Enterprise Networks (EEN)

➔ EC Information desks (contattabili via e-mail o telefono)

ARiAT – Horizon 2020 Annotated Research and Innovation Actions Template

Innovation dimension in Horizon 2020 proposals: set of good practices to understand and write innovation related issues both in Research and Innovation Actions (RIA) and Innovation Actions (IA)


<http://health2market.eu/results/h2020-annotated-template>

The annotated template aims to assist applicants to the Research and Innovation Actions (RIA) and Innovation Actions (IA) of Horizon 2020 Framework Programme for 2014-2020 to better understand the requirements of the templates and better write innovation-related issues in the H2020 proposals. It highlights and emphasise the innovation elements that an excellent project application should contain.

A successful project proposal needs to speak out convincingly to a broad readership encompassing experts from a wide range of fields. While the scientific/technical soundness of a proposal is central to its ultimate success, it is also essential that the **challenges to be addressed**, **opportunities** to be exploited, and **results** to be achieved are clear and understandable to all readers, specifically to Horizon 2020 evaluators. Moreover, the linkage between results to be achieved and their relevance for European policy orientations should be clear, as well as the economic opportunities they will provide for citizens. The **ARiAT Template** has been structured to guide project formulators in presenting information required especially by the criteria of Excellence (criterion 1) and Impact (criterion 2). The Appendices include an example of a business plan executive summary and an example of work packages addressing dissemination and exploitation of results, preparation of market authorisation and market access (related to health topic).

The document is edited by APRE (Italy), Horizon 2020 National Contact Point for Health – Societal Challenge 1, and co-authored by specialists from engage AG (Germany), inno TSD (France), IE Business School (Spain) and SKEMA Business School (France). It reflects the view of the authors, who are experts dealing with H2020 proposals, innovation, exploitation of R&D results, and generally with entrepreneurship and business development on day-to-day basis. Their recommendations are indicated in the document as “**Expert recommendations**” and also include feedback collected from evaluators of H2020 proposals and **concrete examples**.

<http://health2market.eu/results/h2020-annotated-template>





Web-site

Events

Newsletter

Social media

Press

[APRE RESOURCES – COMMUNICATION]



Next relevant events



Horizon 2020 Health Partnering Day 2016

7th July, BRUSSELS

<http://www.fitforhealth.eu/event-created/horizon-2020-health-partnering-day-2016>

Info Day, Horizon 2020 - 'Health, demographic change and wellbeing'

8th July 2016, BRUSSELS

<http://ec.europa.eu/research/index.cfm?pg=events&eventcode=314FDE2A-B120-5C11-0BC24DEE2CA8115E>

PRIMI RISULTATI 2014-2015

SC1 – Health, demographic change and Wellbeing

(DG RTD e DG CONNECT)



PHC - Bando 2014

No. topics	Budget Mill. EUR	Proposte presentate		Proposte finanziate		Tasso di successo	
16	488,2	1056		95		9%	

Partecipazione



No. Partecipanti italiani in proposte presentate	No. Partecipanti italiani finanziati	Tasso di successo partecipanti Italiani
1125	101	8,9%

Coordinamento



No. Proposte presentate a coordinamento italiano	No. Coordinamenti italiani finanziati	Tasso di successo coordinatori Italiani
136 (12,8% del totale EU)	9	6,6%

PHC - Bando 2015

No. topics	Budget Mill. EUR	Proposte presentate		Proposte finanziate		Tasso di successo	
18	543,5	1197		85		7%	

Partecipazione



No. Partecipanti italiani in proposte presentate	No. Partecipanti italiani finanziati	Tasso di successo partecipanti Italiani
1345	80	5,9%

Coordinamento



No. Proposte presentate a coordinamento italiano	No. Coordinamenti italiani finanziati	Tasso di successo coordinatori Italiani
175 (14,6% del totale EU)	6	3,4%



HCO - Bando 2014

No. topics	Budget Mill. EUR	Proposte presentate 	Proposte finanziate 	Tasso di successo 
11	40	47	14	29.7%

Partecipazione



No. Partecipanti italiani in proposte presentate	No. Partecipanti italiani finanziati	Tasso di successo partecipanti Italiani
35	14	40%

Coordinamento



No. Proposte presentate a coordinamento italiano	No. Coordinamenti italiani finanziati	Tasso di successo coordinatori Italiani
2	1	50%

HCO - Bando 2015

No. topics	Budget Mill. EUR	Proposte presentate 	Proposte finanziate 	Tasso di successo 
5	29	26	8	30.7%

Partecipazione



No. Partecipanti italiani in proposte presentate	No. Partecipanti italiani finanziati	Tasso di successo partecipanti Italiani
32	8	25%

Coordinamento



No. Proposte presentate a coordinamento italiano	No. Coordinamenti italiani finanziati	Tasso di successo coordinatori Italiani
5	0	---




Call fiche 2014

Health, Demographic change and Welbeing

- **Bandi:** I dati riassumono i topics scaduti nel 2014 in single stage e doppio stage nel area Personalizing Health and Care
- **Data pubblicazione:** 11 Dicembre 2013
- **Scadenza:** Aprile 2014 e Agosto 2014
- **Budget totale:** 488,2 Mill EUR

Coordinamento Italiano

PHC-2014-two stages
Scadenza: 19 Agosto 2014
60 proposte presentate



- PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways
- PHC 5 – 2014: Health promotion and disease prevention: translating ‘omics’ into stratified approaches
- PHC 6 – 2014: Evaluating existing screening and prevention programmes
- PHC 10 – 2014: Development of new diagnostic tools and technologies: in vitro devices, assays and platforms
- PHC 13 – 2014: New therapies for chronic non-communicable diseases
- PHC 17 – 2014: Comparing the effectiveness of existing healthcare interventions in the elderly
- PHC 23 – 2014: Developing and comparing new models for safe and efficient, prevention oriented health and care systems
- PHC 32 – 2014: Advancing bioinformatics to meet biomedical and clinical needs

Coordinamento Italiano

PHC-2014-two stages

Scadenza: 19 Agosto 2014

(5 coordinatori finanziati su 60 – Tasso successo: 8,3%)

-PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways

-2 coordinatori italiani.

-Keywords: Ageing of the immune system / Parkinson Disease

-PHC 6 – 2014: Evaluating existing screening and prevention programmes

-1 coordinatore italiano.

-Keyword: Chronic Kidney Disease

-PHC 10 – 2014: Development of new diagnostic tools and technologies: in vitro devices, assays and platforms

-2 coordinatori italiani.


-Keywords: Chemotherapeutic drugs / Early cancer diagnosis

PHC-2014-two stages


Scadenza: 19 Agosto 2014



Geographical distribution of coordinators by EU Member State



Geographical distribution of successful coordinators by EU Member State




Retained



Partecipazione Italiana

PHC-2014-two stages
Scadenza: 19 Agosto 2014
560 partecipanti



■ PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways

■ PHC 5 – 2014: Health promotion and disease prevention: translating 'omics' into stratified approaches

■ PHC 6 – 2014: Evaluating existing screening and prevention programmes

■ PHC 10 – 2014: Development of new diagnostic tools and technologies: in vitro devices, assays and platforms

■ PHC 13 – 2014: New therapies for chronic non-communicable diseases


■ PHC 17 – 2014: Comparing the effectiveness of existing healthcare interventions in the elderly

■ PHC 23 – 2014: Developing and comparing new models for safe and efficient, prevention oriented health and care systems

■ PHC 32 – 2014: Advancing bioinformatics to meet biomedical and clinical needs

Partecipazione Italiana

PHC-2014-two stages
Scadenza: 19 Agosto 2014
(44 finanziati su 560
Tasso successo: 7,8%)



■ PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways

■ PHC 5 – 2014: Health promotion and disease prevention: translating 'omics' into stratified approaches

■ PHC 6 – 2014: Evaluating existing screening and prevention programmes

■ PHC 10 – 2014: Development of new diagnostic tools and technologies: in vitro devices, assays and platforms

■ PHC 13 – 2014: New therapies for chronic non-communicable diseases

■ PHC 17 – 2014: Comparing the effectiveness of existing healthcare interventions in the elderly

■ PHC 23 – 2014: Developing and comparing new models for safe and efficient, prevention oriented health and care systems


■ PHC 32 – 2014: Advancing bioinformatics to meet biomedical and clinical needs

PHC-2014-two stages

Scadenza: 19 Agosto 2014




Geographical distribution of all applicants by EU Member State



Evaluated

Geographical distribution of all applicants by EU Member State




Retained



Coordinamento Italiano

PHC-2014-single stage
Scadenza: 15 Aprile 2014
76 proposte presentate



- PHC 7 – 2014: Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens
- PHC 8 – 2014: Vaccine development for poverty-related and neglected infectious diseases: Tuberculosis
- PHC 15 – 2014/2015: Clinical research on regenerative medicine
- PHC 19 – 2014: Advancing active and healthy ageing with ICT: Service robotics within assisted living environments
- PHC 20 – 2014: Advancing active and healthy ageing with ICT: ICT solutions for independent living with cognitive impairment
- PHC 26 – 2014: Self-management of health and disease: citizen engagement and mHealth
- PHC 31 – 2014: Foresight for health policy development and regulation
- PHC 34 – 2014: eHealth interoperability

Coordinamento Italiano

PHC-2014-single stage

Scadenza: 15 Aprile 2014

(4 coordinatori finanziati su 76 – Tasso successo: 5,2%)

-PHC 19 – 2014: Advancing active and healthy ageing with ICT: Service robotics within assisted living environments

-2 coordinatori italiani.

-Keywords: CyberphysicAI social network / Independent Care and Health Monitoring of the Elderly

-PHC 20 – 2014: Advancing active and healthy ageing with ICT: ICT solutions for independent living with cognitive impairment

-1 coordinatore italiano.

-Keyword: Care for ageing people (**Innovation action**)

-PHC 26 – 2014: Self-management of health and disease: citizen engagement and mHealth

-1 coordinatore italiano.


-Keywords: Parkinson's disease management

Partecipazione Italiana

PHC-2014-single stage

Scadenza: 15 Aprile 2014

565 partecipanti (65 RTD + 500 CONNECT)




- PHC 7 – 2014: Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens
- PHC 8 – 2014: Vaccine development for poverty-related and neglected infectious diseases: Tuberculosis
- PHC 15 – 2014/2015: Clinical research on regenerative medicine
- PHC 31 – 2014: Foresight for health policy development and regulation

* *Dati mancanti della partecipazione italiana per topic alla parte del bando CONNECT (PHC-19, PHC-20, PHC-26, PHC-34)*

Partecipazione Italiana

PHC-2014-single stage
Scadenza: 15 Aprile 2014
(57* finanziati su 565)
Tasso successo: 10%)



- PHC 7 – 2014: Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens
- PHC 8 – 2014: Vaccine development for poverty-related and neglected infectious diseases: Tuberculosis
- PHC 15 – 2014/2015: Clinical research on regenerative medicine
- PHC 19 – 2014: Advancing active and healthy ageing with ICT: Service robotics within assisted living environments
- PHC 20 – 2014: Advancing active and healthy ageing with ICT: ICT solutions for independent living with cognitive impairment
- PHC 26 – 2014: Self-management of health and disease: citizen engagement and mHealth
- PHC 31 – 2014: Foresight for health policy development and regulation
- PHC 34 – 2014: eHealth interoperability

(*) 40 Connect + 17 RTD

Call fiche 2015

Health, Demographic change and Welbeing


- **Bandi:** I dati riassumono i topics scaduti nel 2015 in single stage e doppio stage nel area Personalizing Health and Care
- **Data pubblicazione:** 11 Dicembre 2013
- **Scadenza:** Febbraio 2015 e Aprile 2015
- **Budget totale:** 543,5 Mill EUR

Coordinamento Italiano

PHC-2015-single stage_RT D

Scadenza: 24 Febbraio 2015

9 proposte presentate - 0 proposte finanziate




- PHC 9 – 2015: Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS
- PHC 15 – 2015: Clinical research on regenerative medicine
- PHC 33 – 2015: New approaches to improve predictive human safety testing
- TOTALE

Partecipazione Italiana

PHC-2015-single stage_RT D

Scadenza: 24 Febbraio 2015

87 partecipanti – 8 in proposte finanziate (Tasso di successo: 9%)




Coordinamento Italiano

PHC-2015-single stage_CONNECT

Scadenza: 21 Aprile 2015

115 proposte presentate



■ PHC-21-2015: Advancing active and healthy ageing with ICT: Early risk detection and intervention

■ PHC-25-2015: Advanced ICT systems and services for integrated care

■ PHC-27-2015: Self-management of health and disease and patient empowerment supported by ICT

■ PHC-28-2015: Self management of health and disease and decision support systems based on predictive computer modelling used by the patient him or herself

■ PHC-29-2015: Public procurement of innovative eHealth services

■ PHC-30-2015: Digital representation of health data to improve disease diagnosis and treatment

■ TOTALE

Coordinamento Italiano

PHC-2015-single stage_CONNECT

Scadenza: 21 Aprile 2015

(5 coordinatori finanziati su 115 – Tasso successo: 4,3%)

-PHC 21 – 2015: Advancing active and healthy ageing with ICT: Early risk detection and intervention

-2 coordinatori italiani.

-Keywords: Elderly-friendly City services / health monitoring and disease prevention

-PHC 28 – 2015: Self-management of health and disease and decision support systems based on predictive computer modelling used by the patient him or herself

-1 coordinatore italiano.

-Keyword: Neurobehavioural predictive and personalised modelling

-PHC 30 – 2015: Digital representation of health data to improve disease diagnosis and treatment

-2 coordinatori italiani.


-Keywords: Head and neck cancer / coronary artery disease

Partecipazione Italiana

PHC-2015-single stage_CONNECT

Scadenza: 21 Aprile 2015

805 partecipanti – 32 in proposte finanziate (Tasso di successo: 3.9%)



Coordinamento Italiano

PHC-2015-two stage (DG RTD)


Scadenza: 21 Aprile 2015

51 proposte presentate - 1 proposta finanziata

-PHC 14 – 2015: New therapies for rare diseases

-1 coordinatore italiano.

-Keyword: Ataxia-Telangiectasia



■ PHC 2 – 2015: Understanding diseases: systems medicine

■ PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities

■ PHC 4 – 2015: Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions

■ PHC 11 – 2015: Development of new diagnostic tools and technologies: in vivo medical imaging technologies

■ PHC 14 – 2015: New therapies for rare diseases

■ PHC 16 – 2015: Tools and technologies for advanced therapies


■ PHC 18 – 2015: Establishing effectiveness of health care interventions in the paediatric population

■ PHC 22 – 2015: Promoting mental wellbeing in the ageing population

■ PHC 24 – 2015: Piloting personalised medicine in health and care systems

■ TOTALE

Geographical distribution of successful coordinators by EU Member State




Partecipazione Italiana

PHC-2015-two stage


Scadenza: 21 Aprile 2015

453 partecipanti – 40 in proposte finanziate (Tasso di successo: 8,8%)



- PHC 2 – 2015: Understanding diseases: systems medicine
- PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities
- PHC 4 – 2015: Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions
- PHC 11 – 2015: Development of new diagnostic tools and technologies: in vivo medical imaging technologies
- PHC 14 – 2015: New therapies for rare diseases
- PHC 16 – 2015: Tools and technologies for advanced therapies
- PHC 18 – 2015: Establishing effectiveness of health care interventions in the paediatric population
- PHC 22 – 2015: Promoting mental wellbeing in the ageing population
- PHC 24 – 2015: Piloting personalised medicine in health and care systems
- TOTALE

Geographical distribution of all applicants by EU Member State



**Main
listed
proposals**

ERA-Nets finanziate in Horizon 2020 (Bando 2014)



E-Rare-3	ERA-NET rare disease research implementing IRDiRC objectives	AGENCE NATIONALE DE LA RECHERCHE	FR
ERACoSysMed	ERACoSysMed - Collaboration on systems medicine funding to promote the implementation of systems biology approaches in clinical research and medical practice	FORSCHUNGSZENTRUM JUELICH GMBH	DE
JPco-fuND	ERA-NET for establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)	FR
TRANSCAN-2	ERA-NET: Aligning national/regional translational cancer research programmes and activities	MINISTERO DELLA SALUTE	IT

ERA-Nets finanziate in Horizon 2020 (Bando 2015)



ERA-CVD	ERA-NET on cardiovascular diseases to implement joint transnational research projects and set up international cooperations	DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV	DE
JPI-EC-AMR	ERA-NET for establishing synergies between the Joint Programming Initiative on Antimicrobial Resistance Research and Horizon 2020	VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL	SE
NEURON Cofund	ERA NET NEURON in the area of brain-related diseases and disorders of the nervous system	DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV	DE

Bando 2016



Scadenza Febbraio 2016

	CSA	PCP	PPI	RIA	TOTAL
SC1-HCO-10-2016	3				3
SC1-HCO-11-2016	4				4
SC1-HCO-12-2016	21				21
SC1-HCO-13-2016	5				5
SC1-HCO-14-2016	1				1
SC1-HCO-15-2016	1				1
SC1-HCO-16-2016	3				3
SC1-PM-12-2016		13			13
SC1-PM-13-2016			2		2
SC1-PM-18-2016				49	49
TOTAL	38	13	2	49	102

Scadenza Aprile 2016

Topic	Proposals Submitted
SC1-HCO-01-2016 (CSA)	9
SC1-HCO-02-2016 (CSA)	13
SC1-HCO-04-2016 (CSA)	1
SC1-HCO-05-2016 (CSA)	2
SC1-HCO-06-2016 (CSA)	2
SC1-PM-01-2016 (RIA)	16
SC1-PM-04-2016 (RIA)	55
SC1-PM-05-2016 (COFUND-EJP)	1
SC1-PM-06-2016 (RIA)	42
SC1-PM-09-2016 (RIA)	138
SC1-PM-11-2016-2017 (RIA)	32
SC1-PM-21-2016 (RIA)	67
Total	378



GRAZIE PER L'ATTENZIONE!

APRE

Agenzia per la Promozione della Ricerca Europea

via Cavour, 71

00184 - Roma

www.apre.it

Tel. (+39) 06-48939993

Fax. (+39) 06-48902550

Bruno Mourenza

Health NCP

mourenza@apre.it